AFF1 and leukemia: NSG mice developing primary CD133+CRISPRKMT2A::AFF1 leukemia (n = 4) had significantly shorter survival than mice developing CD133– (n = 12) leukemia (Figure 1D; 119 vs 140.7 days median, P = .0004).